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Abstract
Background: Preterm birth is still the leading cause of neonatal morbidity and mortality. The level of
corticotropin-releasing hormone (CRH) is known to be significantly elevated in the maternal plasma at preterm
birth. Although, CRH, CRH-binding protein (CRH-BP), CRH-receptor 1 (CRH-R1) and CRH-R2 have been
identified both at mRNA and protein level in human placenta, deciduas, fetal membranes, endometrium and
myometrium, no corresponding information is yet available on cervix. Thus, the aim of this study was to compare
the levels of the mRNA species coding for CRH, CRH-BP, CRH-R1 and CRH-R2 in human cervical tissue and
myometrium at preterm and term labor and not in labor as well as in the non-pregnant state, and to localize the
corresponding proteins employing immunohistochemical analysis.
Methods: Cervical, isthmic and fundal (from non-pregnant subjects only) biopsies were taken from 67 women.
Subjects were divided in 5 groups: preterm labor (14), preterm not in labor (7), term labor (18), term not in labor
(21) and non-pregnant (7). Real-time RT-PCR was employed for quantification of mRNA levels and the
corresponding proteins were localized by immunohistochemical analysis.
Results: The levels of CRH-BP, CRH-R1 and CRH-R2 mRNA in the pregnant tissues were lower than those in
non-pregnant subjects. No significant differences were observed between preterm and term groups. CRH-BP and
CRH-R2 mRNA and the corresponding proteins were present at lower levels in the laboring cervix than in the
non-laboring cervix, irrespective of gestational age. In most of the samples, with the exception of four myometrial
biopsies the level of CRH mRNA was below the limit of detection. All of these proteins could be detected and
localized in the cervix and the myometrium by immunohistochemical analysis.
Conclusion: Expression of CRH-BP, CRH-R1 and CRH-R2 in uterine tissues is down-regulated during
pregnancy. The most pronounced down-regulation of CRH-BP and CRH-R2 occurred in laboring cervix,
irrespective the length of gestation. The detection of substantial expression of the CRH and its receptor proteins,
as well as receptor mRNA in the cervix suggests that the cervix may be a target for CRH action. Further studies
are required to elucidate the role of CRH in cervical ripening.
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Preterm birth (PTB) is the leading cause of neonatal mor-
bidity and mortality. Despite the existence of strategies for
treatment, the frequency of PTB has not changed signifi-
cantly during the past three decades and the mechanisms
underlying the initiation of both preterm and term labor
remain largely unknown [1,2]. To date, research and treat-
ment of PTB has focused on myometrial contractions but
for successful preterm delivery these contractions must be
coordinated with a softening of the cervix. Cervical soften-
ing involves intensive remodeling of the extracellular
matrix (ECM), with extensive changes in concentration
and composition of collagens [3,4] and proteoglycans
[5,6]. Cytokines and several other mediators, including
estrogen, progesterone, nitric oxide and prostaglandins,
participate in the remodeling of extracellular matrix and
ripening of the human cervix [1,7-9]. This process can be
regarded as an inflammatory reaction associated with ele-
vated levels of cytokines at the time of both preterm and
time labor [10-12].
Corticotropin-releasing hormone (CRH) is the principal
regulator of the hypothalamic-pituitary-adrenal (HPA)
axis. The HPA axis has been of interest in connection with
labor since Liggins induced premature parturition in
sheep with corticotropin and cortisol infusion [13]. CRH
is produced by fetomaternal tissues and secreted into the
maternal circulation, so that during pregnancy the mater-
nal plasma levels of this hormone increase while of the
corresponding binding protein (CRH-BP) is reduced
[14,15]. It has been suggested a "placental clock" model,
which determines the duration of gestation and the tim-
ing of parturition [16]. Patients at risk for preterm birth
have significantly elevated plasma levels of CRH and
lower CRH-BP levels [17]. However, usefulness of mater-
nal plasma CRH as a predictor of preterm birth is contro-
versial [18,19].
CRH, CRH-BP and the receptors for CRH, CRH-R1 and
CRH-R2, together with the corresponding proteins are
expressed in human placenta, deciduas, fetal membranes,
endometrium and myometrium [14,20-27]. However, to
our knowledge, no studies of a similar nature have been
performed on human cervical tissue. Accordingly, our
present aims were to compare the levels of expression of
CRH, CRH-BP, CRH-R1 and CRH-R2 in human cervical
tissue and myometrium in preterm and term labor and
not in labor as well as in the non-pregnant state, and to
localize the corresponding proteins employing immuno-
histochemical analysis.
Methods
Material
The 67 women included in this study were divided into 5
study groups. The two preterm groups consisted of 14
women undergoing preterm labor (PTL) and 7 at preterm
not in labor (PTnotL), delivered by caesarean section prior
to the onset of labor. Premature delivery was defined as
delivery before the 37th week of gestation. The two term
groups included 18 women undergoing term labor (TL)
and 21 at term not in labor caesarean section (TnotL). The
labor groups were in active labor and demonstrated a ripe
cervix, with dilatation more than 4 cm. They were either
delivered vaginally or by emergency caesarean section due
to malpresentation (at preterm) or due to threatening
fetal asphyxia (at term). In all patients delivered by caesar-
ean section, the assessment of cervical dilatation was
established immediately before surgery. Women not in
labor had unripe cervices (with a Bishop score of <5
points) and were delivered by caesarean section prior to
the onset of labor. The preterm indications were suspected
ablatio or intra-uterine growth retardation and the term
indications were breech presentation, humanitarian or
disproportion.
None of the women included in the study suffered from
pre-eclampsia, diabetes or other systemic disease, nor did
any of our subjects demonstrate clinical signs of infection
in connection with parturition or during postpartal
period.
There were no significant differences between these four
groups with respect to maternal age, parity, previous pre-
term births and caesarean sections (Table 1).
The fifth group consisted of 7 non-pregnant (NP) premen-
opausal women undergoing hysterectomy for benign
gynecological conditions such as menorrhagia or dysmen-
orrhea (Table 1). One of these patients was receiving
replacement therapy with thyroid hormone following
thyroidectomy.
Prior to the performance of this study the approval of the
local Ethics Committee of Karolinska Institute (Ref. no.
97-089 and 01-395) and the informed consent of each
subject was received.
Immediately following parturition, caesarean section or
hysterectomy, a biopsy was taken transvaginally (at the 12
o'clock position) from the anterior cervical lip with scis-
sors and tweezers, a technique that our group has applied
for 25 years now to obtain cervical tissue samples includ-
ing squamous and cylindrical epithelium, vessels, glands
and extracellular matrix. In the case of caesarian sections,
biopsies were also taken from the upper edge of the lower
segment incision. Biopsies from non-pregnant myo-
metrium were obtained from the same location and, in
addition, from the fundal region. The samples to be uti-
lized for analysis of mRNA were immediately frozen in
liquid nitrogen and stored thereafter at -70°C. BiopsiesPage 2 of 11
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in a physiological saline solution and subsequently fixed
in 4% formaldehyde solution for a maximum of 24 hours,
followed by dehydration in 70% ethanol and embedment
in paraffin.
The limited amount of tissue available from each woman
did not allow performance of all of the different analyses
on each individual sample.
Tissue homogenization and extraction of RNA
Tissue homogenization was carried out by the help of a
dismembranation apparatus (Retsch KG, Haan, Ger-
many) and total RNA extracted using the Trizol reagent
(Invitrogen, Carlsbad, CA, USA) as described previously
[12].
Treatment with DNAse and reverse transcription (RT)
The concentration of total RNA obtained was determined
on the basis of the OD260 using a DU64® spectrophotom-
eter (Beckman, Palo Alto, CA, USA) and only samples
exhibiting an OD260/OD280 ratio higher than 1.5 were
used for RT-PCR. 2 μg total RNA, pre-treated with 2 μl
RQ1 RNase-Free DNase (Promega, Madison, WI, USA),
was used for RT reaction, which was performed using
SuperScript™ RNase H- Reverse Transcriptase (Invitrogen,
Carlsbad, California, USA) as described elsewhere [12].
The cDNA was stored at -70°C prior to use.
Real-Time RT-PCR
To levels of mRNA encoding CRH, CRH-BP, CRH-R1 and
CRH-R2 were quantified by real-time RT-PCR employing
the Applied Biosystems 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). All determi-
nations were performed in triplicate in Taqman Universal
PCR Master Mix (Applied Biosystems) on 96-well optical
PCR plates. Appropriate primers and probes were pur-
chased from commercially available Taqman® gene
expression assays (Applied Biosystems). Assay IDs and
GenBank Accession numbers: CRH-Hs00174941_m1
(NM_000756), CRH-BP-Hs00181810_m1 (X58022.1),
CRH-R1 – Hs00366363_m1 (L23332.1), CRH-R2-
Hs01120854_m1 (U34587.1). Ribosomal 18S RNA
(X03205.1) was used as an internal standard (Assay ID –
Hs99999901_s1, Applied Biosystems).
For each reaction, 5 μl diluted cDNA (corresponding to 20
ng total RNA in all cases except for CRH, where 500 ng
total RNA was utilized), 12.5 μl Universal Master Mix,
1.25 μl assay mixture and 18.75 μl sterile water was
employed. Real-time PCR reaction was carried out accord-
ing to a standard manufacturer protocol involving 40–55
cycles of denaturation-annealing. The threshold cycles
(CT), at which an increase in reporter fluorescence above
the baseline signal could first be detected, were deter-
mined. The relative levels of the mRNA species of interest
were determined employing serial dilutions of the placen-
tal (for CRH-BP and CRH-R1) or hippocampal (for CRH-
R2) cDNA made from purchased total RNA (Ambion,
Austin, TX, USA) and normalizing against the levels of
18S rRNA detected.
Immunohistochemical analysis
Immunohistochemical analyses were performed on biop-
sies from 21 subjects: 6 non-pregnant, 10 at term not in
labor and 5 at term in labor. In addition to preparation of
the biopsies from 16 of these subjects as described above,
biopsies from 5 women (1 NP, 2 TnotL, 2 TL) were fixed
somewhat differently, i.e., by initial immersion for 2 h at
4°C in a solution containing 4% paraformaldehyde and
14% saturated picric acid in 0.1 M phosphate buffer (pH
6.9), followed by rinsing for at least 24 h in 0.1 M
Sörensen's buffer containing 10% sucrose, 0.01% NaN3
and 0.02% Bacitracin. Serial cryostat sections 14 μm thick
were air-dried.
Tissue sections were stained employing the avidin-bioti-
nylated (ABC)-peroxidase complex method. When ana-
lyzed, they were rewashed in PBS for three times five
minutes. The endogenous peroxidase activity was elimi-
Table 1: Characteristics of the study groups
Parameter Preterm labor (PTL) Term labor (TL) Preterm not in labor 
(PTnotL)
Term not in labor 
(TnotL)
Non-pregnant (NP)
Number of subjects 14 18 7 21 7
Age (median, range) 27.5 (18–37) 28.5 (20–37) 32 (27–35) 32 (25–42) 45 (37–49)
Parity (median, range) 1 (0–3) 1 (0–2) 1 (0–2) 1 (0–3) 1 (0–3)
Previous preterm 
births in the group
1 0 1 2 –
Previous C/S (median, 
range)
0 (0–1) 0 (0–1) 0 (0–0) 0 (0–2) –
Gestational age in 
days (median, range)
237.5 (184–255) 278 (259–292) 193 (183–256) 270 (259–278) –
Treatment with 
corticosteroids
4 0 4 0 –Page 3 of 11
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methanol for 30 minutes followed by washing in PBS/BSA
(0,05%). The slides were incubated overnight with pri-
mary rabbit (CRH) or goat (CRH-BP, CRH-R1, CRH-R2)
polyclonal antibodies (Santa Cruz Biotechnology Inc,
Heidelberg, Germany) directed towards the protein indi-
cated. The dilutions employed for paraffin-embedded sec-
tions were as follows: CRH, 1:25 (sc-10718); CRH-BP,
1:100 (sc-1822); CRH-R1, 1:100 (sc-12381); and CRH-
R2, 1:50 (sc-1826). In the case of air-dried sections, the
antibodies towards CRH were diluted 1:400 and those
against CRH-BP 1:800. Subsequently, the sections were
washed in PBS/BSA and afterwards incubated with horse
anti-goat or horse anti-rabbit the secondary antibody
diluted in blocking sera for 30 min. The sections were
washed with PBS/BSA, incubated with ABC-complex for
30 minutes, and then rewashed in PBS/BSA. The reaction
was developed using the DAB-kit (diaminobenzidine)
from Vector (Burlingame, CA, USA). The slides were then
rinsed in distilled water. Counterstaining was performed
in 10% Mayer's Haematoxylin solution for 3–4 minutes,
thereafter the sections were washed in water. Control sec-
tions were stained in the same manner, but with omission
of the primary antibody. The slides were finally mounted
with glycerolgelatin. In all cases immunoreactivity in the
squamous and glandular epithelium, the stroma and the
vascular endothelium was classified by four independent
observers (AK, GEO, BS and JC or EB) employing conven-
tional light-microscopy.
Statistical analysis
Comparisons between two independent groups were per-
formed utilizing the Mann-Whitney U test. For compari-
son of cervical and isthmic biopsies from the same
patient, the Wilcoxon matched pair test was employed.
When more than two groups were compared, the Kruskal-
Wallis test was applied, followed by multiple comparison
with Bonferroni/Dunn correction. In all cases a p-value of
<0.05 was considered to be statistically significant. All cal-
culations were performed with the STATISTICA 6.0 soft-
ware (StatSoft Inc, Tulsa, OK, USA).
Results
mRNA levels in the cervix
CRH
Utilizing cDNA corresponding to 20 or 500 ng total RNA
for real-time PCR analysis, no CRH mRNA could be
detected in any of the cervical samples (data not shown).
CRH-BP
Although, there were no significant differences in the lev-
els of CRH-BP mRNA levels between preterm and term
respective groups, we did observe a tendency towards a
higher level in the non-pregnant than in the pregnant cer-
vix (Figure 1A). There were significantly higher levels in
the non-pregnant cervix compared to PTL (p = 0.02) and
TL (p < 0.001) cervix. Furthermore, significantly lower lev-
els of CRH-BP mRNA were seen in the laboring cervix
compared to the cervix not in labor at term (p < 0.001). A
tendency towards similar difference was in the preterm
groups, but this difference was not statistically significant.
Comparing non-pregnant, laboring and non-laboring
groups irrespective of gestational age, significantly higher
levels of CRH-BP mRNA were detected in the non-preg-
nant cervix than in the pregnant cervix not in labor (p =
0.03) and in labor (p < 0.001), (Figure 3A). Furthermore,
the level of this mRNA was significantly lower in the
laboring cervix in comparison to not in labor (p =
0.0001).
CRH-R1
The levels of CRH-R1 mRNA were generally low in all the
cervical samples. There were significantly higher levels of
CRH-R1 mRNA in PTnotL cervix than in TnotL (p = 0.02)
(Figure 1B). As in the case of CRH-BP mRNA, there was a
trend towards higher levels of CRH-R1mRNA in non-
pregnant tissues compared to pregnant (Figure 1B). The
differences were statistically significant between TL and
NP cx (p = 0.02), TnotL and NP cx (p < 0.01) and nearly
significant between PTL and NP cx (p = 0.055).
Comparing groups irrespective of gestational age, there
were no differences in the levels of CRH-R1 mRNA
between the laboring and non-laboring groups. The CRH-
R1 mRNA expression was significantly higher in the non-
pregnant cervix compared to the pregnant cervix not in
labor (p < 0.01) and in labor (p < 0.01) (data not shown).
CRH-R2
The levels of CRH-R2 mRNA were very low in all the sam-
ples. There were no significant differences between pre-
term and term respective groups. As in the case of both
CRH-BP and CRH-R1 mRNA, the CRH-R2 mRNA level
was generally higher in the non-pregnant cervix and these
differences with respect to the PTL (p = 0.02) and TL (p =
0.002) groups were statistically significant (Figure 1C).
Furthermore, there was a significantly higher level of
CRH-R2 mRNA in the cervix at term not in labor than in
labor (p = 0.02). The same tendency was observed in the
preterm groups, but not statistically significant.
When the study groups were compared irrespective of ges-
tational age, significantly lower levels of CRH-R2 mRNA
in the laboring (p < 0.01) in comparison to non-laboring
cervix were seen (Figure 3B). In line with CRH-BP and
CRH-R1 data, the highest expression of CRH-R2 mRNA
was in the non-pregnant cervix (Figure 3B).Page 4 of 11
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CRH
When cDNA corresponding to 20 ng total RNA was
employed for analysis, no CRH mRNA was detected in
any of the samples. When a much larger amount (500 ng)
was used, this mRNA species was detected only in two
isthmic samples from PTnoL and two isthmic samples
from TnotL group (data not shown).
CRH-BP
Similar to what was observed in the case of cervix, there
were no significant differences between the levels of CRH-
BP mRNA comparing preterm and term respective groups
(Figure 2A). However, there was a tendency – close to
being statistically significant in the case of TnotL (p =
0.052) – towards higher levels of this mRNA species in the
non-pregnant isthmus and fundus (which contained the
same level) than in the pregnant tissues.
Comparing the CRH-BP mRNA expression between the
cervical and isthmic biopsies respectively, significantly
higher levels in the TnotL cervix than in the corpus (p =
0.003) were observed. There were no significant differ-
ences between the biopsies from corpus in labor and not
in labor irrespective of gestational age. In line with the
results regarding cervical tissue, there were significantly
higher CRH-BP mRNA expression levels in the non-preg-
nant corpus compared to pregnant not in labor (p = 0.02)
and in labor (p = 0.03) (data not shown).
CRH-R1
Again as in the case of the cervix, there were no significant
differences between the low levels of CRH-R1 mRNA
comparing preterm and term groups (Figure 2B). A ten-
dency towards higher levels of CRH-R1 in the non-preg-
nant corpus compared to pregnant was observed (Figure
2B). The difference was statistically significant between
the TnotL and NP corpus (p < 0.05). There were no signif-
icant differences between the levels of CRH-R1 comparing
samples from cervix, isthmus or fundus.
Comparing groups irrespective of gestational age, there
were no differences in the mRNA expression of CRH-R1
between the laboring and non-laboring groups. However,
CRH-R1 mRNA levels were significantly higher in the
non-pregnant corpus compared to pregnant not in labor
(p = 0.0001) (data not shown).
CRH-R2
Once again as in the case of the cervix, there were no sig-
nificant differences between the low levels of CRH-R2
mRNA between preterm and term respective groups.
However, there was a tendency – which was nearly statis-
tically significant in the case of PTL (p = 0.06) – towards
higher levels of this mRNA species in the non-pregnant
Levels of CRH-BP, CRH-R1 and CRH-R2 mRNA in the cervi-cal tissueFigure 1
Levels of CRH-BP, CRH-R1 and CRH-R2 mRNA in 
the cervical tissue. Box and whisker plots represent the 
mRNA levels of (A) CRH-BP, (B) CRH-R1, (C) CRH-R2 in 
the cervical tissue, normalized to ribosomal 18S mRNA. No 
CRH mRNA was detected in any of the cervical samples. The 
studied groups are: preterm labor (PTL), preterm not in 
labor (PTnotL), term labor (TL), term not in labor (TnotL), 
non-pregnant (NP). The numbers of samples analyzed for 
CRH, CRH-BP, CRH-R1 and CRH-R2 in each group are 
shown under the group name in the part A of the figure. Sta-
tistically significant differences are indicated above the plots.Page 5 of 11
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than in the pregnant tissues (Figure 2C). A tendency
towards lower levels of CRH-R2 mRNA was seen in the
laboring groups compared to the groups not in labor,
although this was not statistically significant. There were
no significant differences between the samples from the
cervix, isthmus or fundus.
Comparing study groups irrespective of gestational age,
there were significantly lower levels of CRH-R2 mRNA in
the laboring corpus (p < 0.05) compared the corpus not
in labor (Figure 3C). As in the case of CRH-BP and CRH-
R1 mRNA, the highest level was in the non-pregnant cor-
pus (Figure 3C).
Immunohistochemical findings
CRH, CRH-BP, CRH-R1 and CRH-R2 proteins were iden-
tified in cervix, isthmus and fundus in all study groups.
The corresponding negative control sections demon-
strated no staining (Figure 6). Similar patterns of staining
were obtained with two different fixation procedures.
Although immunohistochemistry is not a quantitative
method, we want to highlight the following observations.
The cervix
CRH was detected in the cervical epithelium, fibroblasts
and vascular endothelium with weaker staining in the
extracellular matrix. This cervical staining was more
intense than that in the corpus, with the most pronounced
staining at term not in labor (Figure 4A, 4B and 4C).
Staining for CRH-BP was weak in the vascular endothe-
lium and the extracellular matrix and even weaker in the
cervical epithelium, with no apparent differences between
the cervix and the corpus. This staining was weaker in the
laboring group compared to the group not in labor (Fig-
ure 4D, 4E and 4F).
Staining for CRH-R1 was observed in the vascular
endothelium and cervical epithelium and heterogene-
ously in the extracellular matrix (Figure 5A, 5B and 5C).
The visual impression was that this staining was more
intense in the laboring cervix.
CRH-R2 was expressed prominently in the squamous epi-
thelium and vascular endothelium, and more weakly in
the extracellular matrix (Figure 5D, 5E and 5F). In this
case staining was weaker in labor compared to not in
labor group.
The corpus (data not shown)
No differences were observed with respect to staining for
CRH, CRH-BP, CRH-R1 and CRH-R2 in biopsies from the
isthmus and fundus of the same non-pregnant patient,
Levels of CRH-BP, CRH-R1 and CRH-R2 mRNA in the uter-ine corpusFigure 2
Levels of CRH-BP, CRH-R1 and CRH-R2 mRNA in 
the uterine corpus. Box and whisker plots represent 
mRNA levels of (A) CRH-BP, (B) CRH-R1, (C) CRH-R2 in 
the isthmic (co) and fundal (fun) samples, normalized to 
ribosomal 18S mRNA. The studied groups are: preterm 
labor (PTL), preterm not in labor (PTnotL), term labor (TL), 
term not in labor (TnotL), non-pregnant (NP). CRH mRNA 
was undetectable in most of these samples with the excep-
tion of two isthmic samples in PTnoL and two isthmic sam-
ples in TnotL groups. The numbers of samples analyzed for 
CRH, CRH-BP, CRH-R1 and CRH-R2 in each group are 
shown under the group name in the part A of the figure. Sta-
tistically significant differences are indicated above the plots.Page 6 of 11
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individuals within the group.
CRH staining was positive in the muscles, fibroblasts and
the extracellular matrix with no apparent differences
between the different groups.
CRH-BP was detected in the muscles, the extracellular
matrix and, most prominently, the vascular endothelium,
with weaker staining in the laboring group than in the
group not in labor, as was also in the case for the cervix.
CRH-R1 was expressed predominantly in the vascular
endothelium, smooth muscle cells and the extracellular
matrix with the most intense staining in the group not in
labor.
Immunohistochemical localization of CRH and CRH-BP in the human cervixFigure 4
Immunohistochemical localization of CRH and CRH-
BP in the human cervix. CRH in the cervical epithelium 
and extracellular matrix in the (A) non-pregnant cervix, (B) 
term not in labor cervix, (C) term in labor cervix. CRH-BP in 
the cervical epithelium and extracellular matrix in the (D) 
non-pregnant cervix, (E) term not in labor cervix, (F) term in 
labor cervix. Prior to staining, these samples were fixed in a 
solution of 4% paraformaldehyde and 14% saturated picric 
acid in 0.1 M phosphate buffer for 2 hours and thereafter 
rinsed in Sörensen's buffer. The brown color represents pos-
itive staining. The magnification is 1 × 100.
Levels of CRH-BP and CRH-R2 mRNA in the studied groups irrespective of gestational ageFigur  3
Levels of CRH-BP and CRH-R2 mRNA in the studied 
groups irrespective of gestational age. Box and whisker 
plots represent mRNA levels of (A) CRH-BP in the cervical 
tissue (cx), (B) CRH-R2 in the cervical tissue (cx), (C) CRH-
R2 in the isthmic biopsies (co) irrespective of gestational age. 
The studied groups are: in labor (Labor), which includes pre-
term and term in labor groups; not in labor group (not Lab), 
which includes preterm and term not in labor groups; non-
pregnant group (NP). The number of samples analyzed in 
each group is shown under the group name. Statistically sig-
nificant differences are indicated above the plots.Page 7 of 11
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cular endothelium and heterogeneously in the extracellu-
lar matrix. The staining was weaker in association with
labor.
Discussion
To our knowledge, this is the first report concerning the
expression and localization of CRH, CRH-BP, CRH-R1
and CRH-R2 in human cervical tissue.
With respect to CRH, the mRNA levels in the cervix and in
most samples from the corpus were below the level of
detection, in agreement with earlier studies, in which
much lower levels of CRH were found in the myometrium
than in the placenta [21]. Of course, we cannot totally
exclude the presence of undetectably low levels of CRH
mRNA in the cervix and this tissue did stain positively for
the CRH protein in connection with our immunohisto-
chemical analysis. However, it appears likely that this cer-
vical CRH originates from the placenta, which is the main
source of this protein in reproductive tissues[21].
In present investigation the levels of CRH-BP, CRH-R1
and CRH-R2 mRNA were found to be lower in the preg-
nant cervix and corpus than in the corresponding tissues
from women who were not pregnant. Again, this finding
is in line with earlier reports that CRH-R1 is down-regu-
lated in the pregnant in comparison to the non-pregnant
myometrium [28,29]. However, there was a discrepancy
between these two previous studies: Stevens and cowork-
ers observed up-regulation of CRH-R1 at the time of labor
[28], whereas, as was also the case in our study, Rod-
riguez-Linares et al found no such significant up-regula-
tion [29]. This discrepancy might be due to the use of
different methodologies: Stevens et al employed semi-
quantitative RT-PCR, Rodriguez-Linares and coworkers
competitive RT-PCR and we used real-time RT-PCR, which
allows more exact quantitation with high fidelity and
identity of the product. The down-regulation of CRH-BP,
CRH-R1 and CRH-R2 in the pregnant uterus could be
related to the elevated levels of CRH in maternal plasma
or, possibly, less CRH effect is needed in pregnancy than
in a non-pregnant state. However, our immunohisto-
chemical analysis revealed no clear reduction in the levels
of the CRH-BP, CRH-R1 and CRH-R2 proteins in connec-
Negative controls for immunohistochemical staining of the CRH, CRH-BP, CRH-R1 and CRH-R2 in the cervixFigure 6
Negative controls for immunohistochemical staining 
of the CRH, CRH-BP, CRH-R1 and CRH-R2 in the 
cervix. Negative controls for the staining of (A) CRH, (B) 
CRH-BP, (C) CRH-R1 and (D) CRH-R2. The magnification is 
1 × 100 in (A) and (B), 1 × 200 in (C) and (D).
Immunohistochemical localization of CRH-R1 and CRH-R2 in the human cervixFigure 5
Immunohistochemical localization of CRH-R1 and 
CRH-R2 in the human cervix. CRH-R1 in the cervical 
epithelium at (A) non-pregnant state, (B) term not in labor, 
(C) term in labor. CRH-R2 in the (A) cervical epithelium at 
non-pregnant state, (B) cervical epithelium and extracellular 
matrix at term not in labor cervix, (C) extracellular matrix at 
term in labor cervix. These samples were fixed in a 4% for-
maldehyde solution for a maximum of 24 hours and subse-
quently dehydrated in 70% ethanol. The brown color 
represents positive staining. The magnification is 1 × 200.Page 8 of 11
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change in physiological function.
There has been much speculation concerning the role of
CRH in connection to preterm labor. Here, we observed
no differences between preterm and term laboring groups,
but the level of CRH-R1 mRNA was significantly higher in
preterm not in labor compared to term not in labor cervix.
However, eight of our preterm patients received corticos-
teroid treatment and earlier studies have shown that
administration of exogenous corticosteroid enhances the
level of maternal plasma CRH, as well as the intensity of
immunohistochemical staining for CRH in the placenta
and fetal membranes [30,31]. Thus, in order to ascertain
whether this treatment influenced our findings, the data
was re-analyzed following elimination of the women
being treated. The only change was that there were no
longer any significant differences between all respective
preterm and term groups (data not shown), which indi-
cates that the difference in cervical CRH-R1 mRNA levels
between women undergoing preterm and term caesarean
section prior to labor was due to corticosteroid treatment.
It would have been preferable from a scientific point of
view to conduct a similar study on a large number of
patients not receiving corticosteroid treatment, but cur-
rent obstetric practice in Sweden and other Western coun-
tries makes it extremely difficult to obtain samples from
patients in preterm labor who have not received exoge-
nous corticosteroids.
Since there appeared to be no essential differences
between preterm and term groups, we decided to analyze
the study groups irrespective of gestational age. This anal-
ysis revealed down-regulation of the levels of both CRH-
R2 and CRH-BP mRNA in the cervix in connection with
labor. This result, in combination with our previous find-
ings that changes in cytokine and 15-hydroxyprostaglan-
din dehydrogenase levels occur in association with labor
irrespective of the length of gestation [12,32], indicate
that the process of preterm cervical ripening is similar to
the one that occurs at term. This decrease in cervical CRH-
BP, both at the mRNA and protein levels at the time of
labor is associated with a similar decrease in the maternal
plasma [15], which means that more CRH is bioavailable
in cervix and can act on the receptors there.
The down-regulation of CRH-R2 in the cervix and myo-
metrium both at mRNA and protein levels at the time of
labor is in some respects to the findings by Jirecek and
coworkers that expression of the CRH-R2 protein in the
myometrium is markedly lower in association with labor
at term [33]. However, these other investigators detected
no differences in the levels of this protein between
patients in preterm labor and not in labor, whereas we
report here the same down-regulation tendency at mRNA
levels irrespective of gestational age. On the other hand,
we performed immunohistochemical analysis only in the
term groups and have no data concerning levels of CRH-
R2 protein in preterm groups. Similar down-regulation of
this receptor has been described in animal studies [34]
and this phenomenon may be important for progression
of normal labor. Since urocortins are the main ligands for
CRH-R2 and play a role in human reproduction [35], it
would be important to look for changes in the levels of
these hormones in the human cervix during pregnancy
and labor.
The detection of substantial expression of the CRH and its
receptor proteins, as well as receptor mRNA in the cervix
suggests that the cervix may be a target for CRH action.
The down-regulation of CRH-R2 and CRH-BP, together
with the most intense immunohistochemical staining for
CRH-R1 in the cervix at the time of labor indicate that
CRH may be involved in cervical ripening. No investiga-
tions concerning a possible effect of this hormone on the
cervix have been published, but there are several mecha-
nisms by which CRH could be involved in the cervical rip-
ening: by up-regulating expression of NOS [36],
enhancing the production of PGE2 and PGF2α [37] or
stimulating secretion of MMP-9 [38]. However, there are
controversial findings concerning the role of CRH in the
release of cytokines in different tissues [39,40].
Earlier studies from our group have identified fetal
fibronectine [41], MMP-8 [42] and Syndican-1 and -3
(unpublished data) in the cervical epithelium. Here, for
the first time, we demonstrate the presence of CRH in the
cervical epithelium with the highest levels at term not in
labor. All these findings support the proposal that the cer-
vical epithelium plays a significant role in the signaling
processes involved in cervical ripening.
Conclusion
CRH-BP, CRH-R1 and CRH-R2 mRNA and the corre-
sponding proteins are expressed in the human cervix. The
CRH protein is also detected in the cervical tissue, which
indicates that the cervix is a target for the action of this
hormone. In comparison to the non-pregnant state, CRH-
BP, CRH-R1 and CRH-R2 are all down-regulated in the
uterine tissues in connection with pregnancy. The most
pronounced down-regulation of CRH-BP and CRH-R2
occurs in the cervix during labor, irrespective of gesta-
tional age. Further studies are required to elucidate the
role of CRH in the process of cervical ripening.
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